Straits Times Index
3,322.48 +0.40 (+0.01%) Nikkei
39,202.26 +164.10 (+0.42%) Hang Seng
18,163.12 -203.83 (-1.11%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,412.21 -185.50 (-0.27%) CMC Crypto 200
1,438.86 -7.81 (-0.54%)
GILD Jan 2025 67.500 put
- Zacks
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
- Zacks
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
